Brokerages Set AstraZeneca (AZN) Price Target at $5,184.40

AstraZeneca (LON:AZN) has earned a consensus rating of “Hold” from the twenty-four brokerages that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is GBX 5,184.40 ($71.63).

A number of equities analysts have recently commented on the stock. Credit Suisse Group reaffirmed an “outperform” rating and set a GBX 5,800 ($80.13) target price on shares of AstraZeneca in a research report on Tuesday, February 20th. Goldman Sachs set a GBX 3,800 ($52.50) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research report on Monday, February 19th. UBS reaffirmed a “neutral” rating on shares of AstraZeneca in a research report on Monday, January 15th. Citigroup reaffirmed a “buy” rating and set a GBX 6,200 ($85.66) target price on shares of AstraZeneca in a research report on Thursday, March 1st. Finally, Barclays reissued a “top pick” rating on shares of AstraZeneca in a report on Friday, March 9th.

LON AZN remained flat at $GBX 4,895.50 ($67.64) during trading on Wednesday. AstraZeneca has a 52-week low of GBX 4,260 ($58.86) and a 52-week high of GBX 5,520 ($76.26).

The firm also recently announced a dividend, which was paid on Monday, March 19th. Investors of record on Thursday, February 15th were given a dividend of GBX 133.60 ($1.85) per share. The ex-dividend date was Thursday, February 15th. This is an increase from AstraZeneca’s previous dividend of $68.90. This represents a yield of 2.8%.

In other AstraZeneca news, insider Philip A. J. Broadley bought 415 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The stock was bought at an average cost of GBX 4,846 ($66.95) per share, for a total transaction of £20,110.90 ($27,785.16).

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply